Drug intelligence / Profile preview

PRI-100

Development stage: Preclinical
Lead developer: Priavoid
Modality: Peptides, Small Molecules

Overview

PRI-100 is a synthetic peptide drug developed by Priavoid GmbH. It functions as an inhibitor of α-synuclein, a protein implicated in the pathogenesis of neurodegenerative diseases such as Parkinson's disease. By inhibiting α-synuclein, PRI-100 aims to prevent or reduce the aggregation of this protein, which is believed to play a key role in neuronal dysfunction and degeneration associated with synucleinopathies. The drug is currently in preclinical development for nervous system diseases, particularly familial Parkinson's disease type 1[1].

Targets

aggregated α-syn (Alpha-synuclein (α-syn))

Beyond the preview

Go deeper on PRI-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRI-100.

Explore the full profile